VistaGen Therapeutics (VTGN) Reports FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder

October 26, 2017 7:41 AM

VistaGen Therapeutics Inc. (NASDAQ: VTGN) announced today that the U.S. Food and Drug Administration (FDA) has authorized the Company to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found